CN109206389A - 异土木香内酯衍生物，其药物组合物及其用途 - Google Patents

异土木香内酯衍生物，其药物组合物及其用途 Download PDF

Info

Publication number
CN109206389A
CN109206389A CN201710528898.3A CN201710528898A CN109206389A CN 109206389 A CN109206389 A CN 109206389A CN 201710528898 A CN201710528898 A CN 201710528898A CN 109206389 A CN109206389 A CN 109206389A
Authority
CN
China
Prior art keywords
compound
cdcl
nmr
mhz
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710528898.3A
Other languages
English (en)
Other versions
CN109206389B (zh
Inventor
张泉
陈悦
高瀛岱
丁亚辉
李晔
连利辉
戈伟智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hematology Hospital Of Chinese Academy Of Medical Sciences Institute Of Hematology
Accendatech Co Ltd
Nankai University
Original Assignee
Hematology Hospital Of Chinese Academy Of Medical Sciences Institute Of Hematology
Accendatech Co Ltd
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hematology Hospital Of Chinese Academy Of Medical Sciences Institute Of Hematology, Accendatech Co Ltd, Nankai University filed Critical Hematology Hospital Of Chinese Academy Of Medical Sciences Institute Of Hematology
Priority to CN201710528898.3A priority Critical patent/CN109206389B/zh
Publication of CN109206389A publication Critical patent/CN109206389A/zh
Application granted granted Critical
Publication of CN109206389B publication Critical patent/CN109206389B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种异土木香内酯衍生物，其药物组合物及其用途，特别是式（I）所示的异土木香内酯衍生物或其盐药物化合物，在制备治疗癌症的药物和在制备治疗癌症的辅助药物中的用途，含有治疗有效量的异土木香内酯衍生物（I）或其盐及药学上可接受的载体的药物组合物或与其他抗癌药物的组合物。

Description

异土木香内酯衍生物，其药物组合物及其用途
技术领域
本发明属于药物技术领域，具体地说，涉及异土木香内酯衍生物或其盐，以其为有效成分的治疗癌症或辅助治疗癌症的药物组合物，以及该药物化合物和组合物在制备抗癌或辅助抗癌药物中的应用。
背景技术
倍半萜内酯是一种大而多样的天然产物。近年来，各种倍半萜内酯的抗癌性质引起了科学家们极大的兴趣，异土木香内酯能够抑制炎症反应，防止增殖和诱导凋亡的多生物活性的倍半萜内酯类化合物之一，药理学的研究领域已经证实了倍半萜内酯对各种人癌细胞系的抗癌活性。
土木香是一种富含倍半萜内酯类化合物的植物，生长在我国大部分地区，其根茎具有一定的抗炎、抗菌、抗肿瘤活性，异土木香内酯可以从土木香中分离得到。
从土木香中分离得到的异土木香内酯属于[6+6+5]型的桉叶烷型倍半萜内酯类结构，其活性基团就是C环上的α，β不饱和内酯，它能够选择性的杀死白血病细胞。但是其水溶性、血浆稳定性较差，而且活性也较低，有望通过对其进行结构修饰来进一步提高其活性、水溶性以及血浆稳定性。本发明合成了异土木香内酯的衍生物或其盐，以其为有效成分的治疗癌症或辅助治疗癌症的药物组合物，以及该药物化合物和组合物在制备抗癌或辅助抗癌药物中的应用。
发明内容
本发明提供了一种异土木香内酯的衍生物或其盐，含有效量的式（Ⅰ）异土木香内酯衍生物或其盐及可药用载体的治疗癌症的药物组合物或与其他抗癌药物的组合物，其制备方法，以及式（Ⅰ）异土木香内酯衍生物或其盐及其药物组合物在制备治疗癌症药物中的应用。
为了实现本发明的上述目的，本发明提供如下的技术方案：
一种如下式（I）的化合物，
（I）
其中，R为烷基、环烷基、烯基、芳基、烷基芳基、芳基烷基、芳基烯基、杂环基、吡啶环基、芳氧烷基.。
根据上述的化合物，化合物为3–42，
本发明还提供了一种式（I）的异土木香内酯衍生物或其盐在制备治疗癌症的药物中的用途，其中癌症为白血病。
本发明还提供了一种式（I）的异土木香内酯衍生物或其盐在制备治疗癌症的辅助药物中的用途，其中癌症为白血病。
本发明还提供了一种用于治疗癌症的药物组合物，其中含有有效量的式（I）的异土木香内酯衍生物和药学上可接受的载体或与其他抗癌药物的组合物。
本发明还提供了式3–42化合物在制备治疗癌症的药物中的用途，其中癌症为白血病。
本发明还提供了式3–42化合物在制备治疗癌症的辅助药物中的用途，其中癌症为白血病。
本发明还提供了一种用于治疗癌症的药物组合物，其中含有有效量的式3–42化合物和药学上可接受的载体或与其他抗癌药物的组合物。
具体实施方式
为了理解本发明，下面以实施例进一步说明本发明，但不意于限制本发明的保护范围。
实施例1：
结构式如下式的制备路线：
化合物2的合成
在0℃下，将SeO2（1990.0 mg, 17.93 mmol）溶解在重蒸的二氯甲烷（DCM）（199.0 mL）中，加入干燥的t-BuOOH（6.4 mL），30分钟后，将化合物1异土木香内酯（11940.0 mg, 51.39mmol）溶解在重蒸的二氯甲烷（199.0 mL）中缓慢的加入到上述体系中，反应体系在室温下搅拌24小时，TLC检测反应完之后，加入饱和的硫代硫酸钠溶液（200.0 mL），用二氯甲烷萃取三次，有机相用无水硫酸镁（MgSO4）干燥，减压浓缩，过硅胶色谱柱（石油醚/乙酸乙酯=5:1至2:1）得化合物2（白色无定型固体，2585.5 mg，产率44.9 %），回收原料6554.6 mg。1HNMR (400 MHz, CDCl3) δ 6.10 (s, 1H), 5.57 (s, 1H), 4.97 (s, 1H), 4.52 (d, J =27.1 Hz, 2H), 4.30 (s, 1H), 2.98 (dt, J = 11.9, 5.8 Hz, 1H), 2.40 (d, J =12.8 Hz, 1H), 2.17 (d, J = 15.5 Hz, 1H), 1.77 (s, 1H), 1.73 (s, 2H), 1.68 (d,J = 11.7 Hz, 2H), 1.55 (d, J = 15.4 Hz, 1H), 1.33 (q, J = 12.2, 11.5 Hz, 2H),0.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.7, 150.3, 142.2, 120.3, 109.9,76.9, 73.3, 41.1, 40.5, 40.3, 35.8, 34.2, 29.1, 27.1, 17.0. HRMS (ESI) calcdfor C15H20O3 [M+H]+ 249.1485, found 249.1483.
化合物3的合成
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.87 – 5.76 (m, 1H), 5.59 (s,1H), 5.36 (s, 1H), 5.12 (s, 1H), 5.09 – 4.96 (m, 2H), 4.69 (s, 1H), 4.51 (s,1H), 3.01 (dt, J = 12.0, 6.3 Hz, 2H), 2.45 – 2.31 (m, 4H), 2.22 (d, J = 15.1Hz, 3H), 1.80 (s, 1H), 1.71 (dd, J = 11.6, 7.2 Hz, 1H), 1.56 (d, J = 11.0 Hz,2H), 1.43 – 1.31 (m, 2H), 0.83 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 145.5,141.9, 171.9, 170.4, 136.7, 120.3, 115.4, 112.5, 75.2, 41.4, 40.9, 40.4,40.4, 36.4, 33.8, 33.8, 28.9, 27.0, 26.9, 17.0. HRMS (ESI) calcd for C20H26O4[M+H]+ 331.1904, found 331.1907.
化合物4的合成
1H NMR (400 MHz, CDCl3) δ 6.10 (s, 1H), 5.57 (s, 1H), 5.30 (s, 1H), 5.09(s, 1H), 4.67 (s, 1H), 4.49 (t, J = 4.1 Hz, 1H), 3.07 – 2.94 (m, 1H), 2.50(d, J = 7.0 Hz, 1H), 2.19 (d, J = 13.8 Hz, 2H), 1.77 (d, J = 7.2 Hz, 2H),1.72–1.66 (m, 1H), 1.54 (dd, J = 15.7, 4.6 Hz, 2H), 1.41 – 1.32 (m, 2H), 1.13(t, J = 7.0 Hz, 6H), 0.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 176.0, 170.5,145.6, 142.0, 120.4, 112.5, 76.7, 75.0, 41.6, 41.1, 40.4, 36.5, 34.3, 33.9,27.1, 27.0, 19.2, 18.9, 17.1. HRMS (ESI) calcd for C19H26O4 [M+H]+ 319.1904,found 319.1902.
化合物5的合成
1H NMR (400 MHz, CDCl3) δ 6.12 (s, 1H), 5.58 (s, 1H), 5.34 (t, J = 2.4Hz, 1H), 5.11 (s, 1H), 4.68 (s, 1H), 4.51 (t, J = 4.2 Hz, 1H), 3.00 (dt, J =11.9, 6.3 Hz, 1H), 2.28 (t, J = 7.5 Hz, 2H), 2.20 (d, J = 15.3 Hz, 2H), 1.78(dd, J = 7.3, 3.7 Hz, 2H), 1.70 (dd, J = 16.4, 7.0 Hz, 1H), 1.62–1.55 (m,3H), 1.53 (d, J = 5.9 Hz, 1H), 1.39 (s, 1H), 1.37–1.30 (m, 3H), 0.89 (t, J =7.3 Hz, 3H), 0.81 (s, 3H); 13C NMR (100MHz, CDCl3) δ 172.9, 170.5, 145.7,142.0, 120.4, 112.5, 76.7, 75.1, 41.6, 41.1, 40.5, 36.5, 34.5, 33.9, 27.2,27.1, 27.0, 22.3, 17.1, 13.8. HRMS (ESI) calcd for C20H28O4 [M+H]+ 333.2060,found 333.2054.
化合物6的合成
1H NMR (400 MHz, CDCl3) δ 6.11 (s, 1H), 5.57 (s, 1H), 5.33 (s, 1H), 5.10(s, 1H), 4.67 (s, 1H), 4.53–4.46 (m, 1H), 2.99 (dt, J = 11.9, 6.3 Hz, 1H),2.26 (t, J = 7.5 Hz, 2H), 2.21 (s, 1H), 2.17 (s, 1H), 1.77 (dd, J = 6.5, 2.9Hz, 2H), 1.69 (ddd, J = 14.0, 7.0, 2.5 Hz, 1H), 1.62 – 1.54 (m, 3H), 1.54 –1.49 (m, 1H), 1.37 (d, J = 6.8 Hz, 1H), 1.34 (d, J = 6.0 Hz, 1H), 1.27 (dd, J= 6.8, 3.1 Hz, 3H), 1.23 (s, 1H), 0.86 (t, J = 6.9 Hz, 3H), 0.80 (s, 3H); 13CNMR (100 MHz, CDCl3) δ 172.8, 170.5, 145.6, 142.0, 120.4, 112.5, 76.7, 75.0,41.5, 41.0, 40.4, 36.5, 34.7, 33.9, 31.3, 27.1, 27.0, 24.8, 22.4, 17.1, 14.0.HRMS (ESI) calcd for C21H30O4 [M+H]+ 347.2217, found 347.2212.
化合物7的合成
1H NMR (400 MHz, CDCl3) δ 6.11 (s, 1H), 5.57 (s, 1H), 5.33 (s, 1H), 5.10(s, 1H), 4.67 (s, 1H), 4.52 – 4.47 (m, 1H), 2.99 (dt, J = 11.9, 6.4 Hz, 1H),2.28 (s, 2H), 2.19 (d, J = 15.3 Hz, 2H), 1.81 – 1.74 (m, 2H), 1.69 (dd, J =13.9, 7.0 Hz, 1H), 1.61 – 1.54 (m, 3H), 1.52 (d, J = 4.6 Hz, 1H), 1.40 – 1.35(m, 1H), 1.26 (s, 3H), 1.25 (s, 3H), 1.24 (s, 2H), 0.84 (t, J = 6.8 Hz, 4H),0.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.9, 170.5, 145.6, 142.0, 120.4,112.5, 76.7, 75.0, 41.5, 41.0, 40.4, 36.5, 34.8, 33.9, 31.8, 29.1, 29.0,27.1, 27.0, 25.1, 22.7, 17.1, 14.1. HRMS (ESI) calcd for C23H34O4 [M+H]+375.2530, found 375.2524.
化合物8的合成
1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 16.0 Hz, 1H), 7.53 (d, J = 5.8 Hz,2H), 7.45–7.34 (m, 3H), 6.45 (d, J = 16.0 Hz, 1H), 6.15 (s, 1H), 5.60 (s,1H), 5.49 (s, 1H), 5.20 (s, 1H), 4.75 (s, 1H), 4.54 (t, J = 4.2 Hz, 1H), 3.03(dt, J = 11.8, 6.2 Hz, 1H), 2.28 (dd, J = 21.1, 14.4 Hz, 2H), 1.96 – 1.80 (m,2H), 1.75 (dd, J = 13.9, 7.0 Hz, 1H), 1.63 (td, J = 15.6, 14.3, 4.8 Hz, 2H),1.41 (dd, J = 26.9, 14.0 Hz, 2H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ170.6, 166.2, 145.6, 144.9, 142.0, 134.5, 130.4, 129.0, 128.2, 120.6, 118.6,112.9, 76.8, 75.5, 41.7, 41.1, 40.5, 36.6, 34.0, 27.2, 27.1, 17.2. HRMS (ESI)calcd for C24H26O4 [M+H]+ 379.1904, found 379.1903 .
化合物9的合成
1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 17.9 Hz, 1H), 7.49 (d, J = 6.5 Hz,2H), 6.96 – 6.86 (m, 2H), 6.32 (d, J = 18.6 Hz, 1H), 6.15 (s, 1H), 5.60 (s,1H), 5.48 (s, 1H), 5.20 (s, 1H), 4.74 (s, 1H), 4.54 (s, 1H), 3.85 (s, 3H),3.08 – 2.98 (m, 1H), 2.28 (dd, J = 22.7, 14.2 Hz, 2H), 1.89 (t, J = 17.2 Hz,2H), 1.64 (d, J = 12.4 Hz, 2H), 1.41 (dd, J = 25.7, 12.2 Hz, 3H), 0.87 (s,3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 166.5, 161.5, 145.8, 144.5, 142.1,129.8, 127.3, 120.5, 116.1, 114.4, 112.8, 76.8, 75.3, 55.5, 41.7, 41.2, 40.6,36.7, 34.1, 27.3, 27.2, 17.2. HRMS (ESI) calcd for C25H28O5 [M+H]+ 409.2004,found 409.2008.
化合物10的合成
1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 16.1 Hz, 1H), 7.51 (d, J = 9.2 Hz,1H), 7.44 – 7.31 (m, 1H), 6.96 (t, J = 7.6 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H),6.52 (d, J = 16.1 Hz, 1H), 6.14 (s, 1H), 5.59 (s, 1H), 5.48 (t, J = 2.6 Hz,1H), 5.20 (s, 1H), 4.74 (s, 1H), 4.53 (t, J = 5.4 Hz, 1H), 3.89 (s, 3H), 3.02(dt, J = 11.9, 6.6 Hz, 1H), 2.31 (d, J = 12.4 Hz, 1H), 2.25 (d, J = 14.3 Hz,1H), 1.96 – 1.89 (m, 1H), 1.74 (dt, J = 15.0, 7.9, 3.9 Hz, 1H), 1.69 – 1.63(m, 1H), 1.62 – 1.56 (m, 1H), 1.43 (d, J = 11.5 Hz, 1H), 1.40 – 1.31 (m, 1H),1.25 (s, 1H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 166.7, 158.4,145.8, 142.1, 140.4, 131.6, 129.0, 123.5, 120.8, 120.5, 119.1, 112.7, 111.3,75.3, 55.7, 41.7, 41.2, 40.6, 36.7, 34.1, 29.8, 27.3, 27.1, 17.2. HRMS (ESI)calcd for C25H28O5 [M+H]+ 409.2010, found 409.2007.
化合物11的合成
1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 16.1 Hz, 1H), 7.04 (s, 1H), 6.95 –6.80 (m, 2H), 6.48 (d, J = 16.1 Hz, 1H), 6.15 (s, 1H), 5.60 (s, 1H), 5.48 (s,1H), 5.20 (s, 1H), 4.74 (s, 1H), 4.53 (s, 1H), 3.82 (d, J = 21.3 Hz, 6H),3.10– 2.97 (m, 1H), 2.28 (dd, J = 25.6, 13.9 Hz, 2H), 1.88 (d, J = 23.2 Hz,2H), 1.60 (d, J = 10.3 Hz, 3H), 1.41 (dd, J = 25.2, 12.7 Hz, 3H), 0.87 (s,3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 166.6, 153.6, 152.9, 145.8, 142.1,140.1, 124.1, 120.5, 119.3, 117.1, 113.6, 112.8, 112.6, 76.8, 75.4, 56.3,55.9, 41.7, 41.2, 40.6, 36.7, 34.1, 27.27, 27.1, 17.3. HRMS (ESI) calcd forC26H30O6 [M+H]+ 439.2115, found 439.2114.
化合物12的合成
1H NMR (400 MHz, CDCl3) δ 6.10 (s, 1H), 5.56 (s, 1H), 5.32 (s, 1H), 5.09(s, 1H), 4.67 (s, 2H), 4.49 (t, J = 4.0 Hz, 1H), 3.12 (d, J = 6.3 Hz, 2H),3.01 (dt, J = 11.6, 5.9 Hz, 1H), 2.31 (t, J = 7.3 Hz, 2H), 2.19 (t, J = 13.8Hz, 2H), 1.83 – 1.73 (m, 4H), 1.69 (dd, J = 13.8, 5.0 Hz, 1H), 1.60 – 1.49(m, 2H), 1.39 (s, 9H), 1.32 (s, 1H), 1.30 – 1.20 (m, 1H), 0.79 (s, 3H); 13CNMR (100 MHz, CDCl3) δ 172.2, 170.5, 156.0, 145.5, 142.0, 120.4, 112.7, 79.2,76.7, 75.4, 41.5, 41.0, 40.4, 40.0, 36.4, 33.9, 32.1, 28.5, 27.1, 27.0, 25.5,17.1. HRMS (ESI) calcd for C24H35NO6 [M+H]+434.2537, found 434.2536.
化合物13的合成
1H NMR (400 MHz, CDCl3) δ 6.11 (s, 1H), 5.59 (d, J = 3.1 Hz, 1H), 5.33(s, 1H), 5.10 (s, 4H), 4.69 (s, 1H), 4.50 (s, 1H), 3.19 – 2.70 (m, 4H), 2.46– 2.30 (m, 2H), 2.17 (t, J = 14.8 Hz, 2H), 1.92 (s, 2H), 1.77 (s, 2H), 1.56(d, J = 10.4 Hz, 3H), 1.37 (d, J = 11.8 Hz, 1H), 0.81 (s, 3H); 13C NMR (100MHz, CDCl3) δ 172.2, 170.6, 142.0, 120.6, 112.9, 76.8, 76.0, 41.5, 40.9,40.4, 36.4, 34.4, 33.9, 31.7, 29.8, 27.1, 17.3, 17.1. HRMS (ESI) calcd forC19H27NO4 [M+H]+ 334.2013, found 334.2013.
化合物14的合成
1H NMR (400 MHz,CDCl3) δ 6.03 (s, 1H), 5.52 (s, 1H), 5.26 (s, 1H), 5.03(s, 1H), 4.61 (s, 1H), 4.43 (t, J = 3.9 Hz, 1H), 3.92 (s, 2H), 2.96 (dt, J =11.6, 6.1 Hz, 1H), 2.74 (s, 2H), 2.35 (t, J = 11.0 Hz, 1H), 2.15 – 2.08 (m,2H), 1.78 (s, 2H), 1.73 – 1.67 (m, 2H), 1.63 (dd, J = 12.8, 5.9 Hz, 1H), 1.49(dd, J = 15.3, 5.1 Hz, 4H), 1.35 (s, 9H), 1.24 (d, J = 13.2 Hz, 1H), 0.73 (s,3H); 13C NMR (100 MHz, CDCl3) δ 173.2, 170.3, 154.5, 145.2, 141.8, 120.3,112.6, 79.4, 76.4, 75.1, 41.4, 41.2, 40.8, 40.1, 36.3, 33.7, 28.3, 28.0,27.8, 27.0, 26.9, 26.8, 16.9. HRMS (ESI) calcd for C26H37NO6 [M+Na]+ 482.2513,found 482.2508.
化合物15的合成
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.59 (s, 1H), 5.34 (s, 1H), 5.11(s, 1H), 4.68 (s, 1H), 4.51 (s, 1H), 3.00 (dt, J = 11.6, 5.8 Hz, 1H), 2.81(d, J = 10.7 Hz, 2H), 2.26 (s, 3H), 2.25 – 2.16 (m, 3H), 1.97 (t, J = 11.5Hz, 2H), 1.88 (s, 2H), 1.79 (s, 1H), 1.77 (s, 2H), 1.70 (dd, J = 14.1, 7.5Hz, 2H), 1.54 (d, J = 12.5 Hz, 2H), 1.38 (d, J = 18.7 Hz, 2H), 1.33 – 1.21(m, 1H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.0, 170.5, 145.5, 142.0,120.5, 112.7, 76.7, 75.2, 55.1, 55.1, 46.5, 41.7, 41.2, 41.1, 40.5, 36.6,34.0, 28.6, 28.4, 27.2, 27.1, 17.1; HRMS (ESI) calcd for C22H31NO4 [M+H]+374.2326, found 374.2318.
化合物16的合成
1H NMR (400 MHz, CDCl3) δ 8.06 – 8.00 (m, 2H), 7.57 (t, J = 7.4 Hz, 1H),7.45 (t, J = 7.6 Hz, 2H), 6.14 (s, 1H), 5.60 (d, J = 2.5 Hz, 1H), 5.59 (s,1H), 5.25 (s, 1H), 4.77 (s, 1H), 4.54 (dd, J = 4.7, 3.7 Hz, 1H), 3.09 – 2.93(m, 1H), 2.33 (d, J = 11.3 Hz, 1H), 2.30 – 2.24 (m, 1H), 2.02 – 1.85 (m, 2H),1.79 – 1.67 (m, 2H), 1.62 (dd, J = 15.6, 4.7 Hz, 1H), 1.49 (dd, J = 10.2, 3.1Hz, 1H), 1.38 (dd, J = 26.1, 12.5 Hz, 1H), 0.89 (s, 3H);13C NMR (100 MHz,CDCl3) δ 169.5, 164.4, 144.4, 140.9, 131.9, 129.8, 128.5, 127.4, 119.4,111.9, 75.6, 74.8, 40.7, 40.0, 39.3, 35.7, 32.9, 26.2, 25.9, 16.1; HRMS (ESI)calcd for C22H24O4 [M+H]+ 353.1753, found 353.1753.
化合物17的合成
1H NMR (400 MHz, CDCl3) δ 6.12 (s, 1H), 5.59 (s, 1H), 5.38 (s, 1H), 5.15(s, 1H), 4.74 (s, 1H), 4.51 (t, J = 3.9 Hz, 1H), 3.81 (s, 2H), 3.07 – 2.95(m, 1H), 2.32 – 2.15 (m, 2H), 1.83 (dt, J = 13.1, 6.7 Hz, 2H), 1.75 – 1.70(m, 1H), 1.59 (ddd, J = 19.6, 14.5, 5.0 Hz, 2H), 1.44 – 1.29 (m, 2H), 0.82(s, 3H); 13C NMR(100MHz,CDCl3) δ 170.6, 166.2, 144.8, 142.0, 120.6, 113.6,77.6, 76.7, 41.5, 41.0, 40.4,36.3,33.9,27.0,26.9,26.5,17.1; HRMS (ESI) calcdfor C17H22BrO4 [M+H]+ 369.0696, found 369.0695.
化合物18的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (d, J = 0.7 Hz, 1H), 5.59 (s, 1H), 5.34(t, J = 2.6 Hz, 1H), 5.13 (s, 1H), 4.70 (s, 1H), 4.52 (dd, J = 4.8, 3.5 Hz,1H), 3.11 (m, 1H), 3.06 – 2.95 (m, 1H), 2.32 – 2.11 (m, 6H), 1.94 (m, 2H),1.80 (m, 2H), 1.72 (m, 1H), 1.61 – 1.50 (m, 2H), 1.43 – 1.29 (m, 2H), 0.83(s, 3H); 13C NMR (100 MHz, CDCl3) δ 174.5, 170.5, 145.7, 142.1, 120.4, 112.5,76.7, 75.0, 41.6, 41.1, 40.5, 38.5, 36.5, 33.9, 27.1, 27.0, 25.4, 25.2, 18.5,17.1; HRMS (ESI) calcd for C23H26O4 [M+H]+ 331.1909, found 331.1906.
化合物19的合成
1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.2 Hz, 2H), 8.18 (d, J = 7.7 Hz,2H), 6.14 (s, 1H), 5.64 (s, 1H), 5.59 (s, 1H), 5.27 (s, 1H), 4.81 (s, 1H),4.54 (t, J = 4.7 Hz, 1H), 3.05 (dt, J = 11.8, 6.0 Hz, 1H), 2.29 (m, 2H), 1.98(m, 2H), 1.82 – 1.69 (m, 2H), 1.63 (dd, J = 15.7, 4.5 Hz, 1H), 1.52 (d, J =13.4 Hz, 1H), 1.39 (q, J = 13.0 Hz, 1H), 0.89 (s, 3H); 13C NMR (100 MHz,CDCl3) δ 170.5, 163.7, 150.6, 144.9, 141.9, 136.3, 130.7, 123.7, 120.6,113.8, 77.2, 76.6, 42.0, 41.1, 40.4, 36.8, 34.1, 27.2, 27.0, 17.1; HRMS (ESI)calcd for C22H23NO6 [M+H]+ 398.1604, found 398.1601.
化合物20的合成
1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 8.3 Hz,2H), 6.13 (s, 1H), 5.58 (s, 2H), 5.23 (s, 1H), 4.75 (s, 1H), 4.53 (s, 1H),3.86 (s, 3H), 3.03 (dt, J = 11.7, 5.9 Hz, 1H), 2.32 (d, J = 12.5 Hz, 1H),2.26 (d, J = 15.6 Hz, 1H), 1.91 (m, 2H), 1.77 – 1.68 (m, 2H), 1.61 (dd, J =15.6, 4.4 Hz, 1H), 1.47 (d, J = 13.1 Hz, 1H), 1.38 (q, J = 12.8 Hz, 1H), 0.88(s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 165.3, 163.4, 145.7, 142.0, 131.7,123.3, 120.5, 113.7, 112.9, 76.7, 75.6, 55.6, 41.9, 41.2, 40.5, 36.9, 34.1,27.4, 27.1, 17.2; HRMS (ESI) calcd for C23H26O5 [M+H]+ 383.1858, found 383.1856.
化合物21的合成
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 7.9 Hz,2H), 6.02 (s, 1H), 5.47 (s, 2H), 5.12 (s, 1H), 4.65 (s, 1H), 4.42 (t, J = 4.2Hz, 1H), 2.92 (dt, J = 11.8, 6.1 Hz, 1H), 2.30 (s, 3H), 2.22 (d, J = 12.5 Hz,1H), 2.15 (d, J = 15.5 Hz, 1H), 1.81 (m, 2H), 1.68 – 1.56 (m, 2H), 1.51 (dd,J = 15.6, 4.6 Hz, 1H), 1.37 (d, J = 13.1 Hz, 1H), 1.27 (q, J = 12.7 Hz, 1H),0.77 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 165.6, 145.6, 143.6, 142.0,129.6, 129.2, 128.1, 120.5, 112.9, 76.7, 75.7, 41.8, 41.1, 40.4, 36.8, 34.0,27.3, 27.0, 21.7, 17.2; HRMS (ESI) calcd for C23H26O4 [M+H]+ 367.1909, found367.1910.
化合物22的合成
1H NMR (400 MHz, CDCl3) δ 6.12 (s, 1H), 5.58 (s, 1H), 5.33 (s, 1H), 5.11(s, 1H), 4.69 (s, 1H), 4.50 (s, 1H), 3.01 (dt, J = 11.6, 5.9 Hz, 1H), 2.21(m, 2H), 2.03 (s, 3H), 1.82 – 1.67 (m, 3H), 1.65 – 1.49 (m, 2H), 1.36 (m,2H), 0.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 170.1, 145.7, 142.1,120.4, 112.6, 76.7, 75.4, 41.5, 41.1, 40.5, 36.4, 33.9, 27.1, 27.0, 21.6,17.1; HRMS (ESI) calcd forC23H26O4 [M+H]+ 291.1596, found 291.1596.
化合物23的合成
1H NMR (400 MHz, CDCl3) δ 6.95 (dq, J = 15.5, 6.9 Hz, 1H), 6.13 (s, 1H),5.84 (d, J = 15.5, 1H), 5.58 (s, 1H), 5.39 (s, 1H), 5.14 (s, 1H), 4.70 (s,1H), 4.51 (t, J = 4.2 Hz, 1H), 3.01 (dt, J = 11.9, 6.0 Hz, 1H), 2.23 (m, 2H),1.87 (d, J = 6.9, 3H), 1.85 – 1.78 (m, 2H), 1.75 – 1.69 (m, 1H), 1.64 – 1.53(m, 2H), 1.42 – 1.30 (m, 2H), 0.83 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5,165.5, 145.6, 144.6, 141.9, 123.1, 120.4, 112.6, 76.6, 75.0, 41.5, 41.0,40.4, 36.5, 33.9, 27.1, 27.0, 18.0, 17.1; HRMS (ESI) calcd for C19H24O4 [M+H]+ 317.1753, found 317.1756.
化合物24的合成
1H NMR (400 MHz, CDCl3) δ 6.40 (d, J = 17.3 Hz, 1H), 6.15 (s, 1H), 6.12(dd, J = 17.3, 10.4 Hz, 1H), 5.83 (d, J = 10.4 Hz, 1H), 5.60 (s, 1H), 5.44(s, 1H), 5.18 (s, 1H), 4.73 (s, 1H), 4.52 (t, J = 4.6 Hz, 1H), 3.02 (dt, J =11.9, 6.1 Hz, 1H), 2.31 – 2.19 (m, 2H), 1.85 (m, 2H), 1.76 – 1.66 (m, 2H),1.64 (m, 1H), 1.56 (m, 1H), 1.47 – 1.30 (m, 2H), 0.85 (s, 3H); 13C NMR (100MHz, CDCl3) δ 170.6, 165.3, 145.5, 142.0, 130.7, 129.0, 120.6, 113.0, 76.7,75.6, 41.7, 41.1, 40.5, 36.6, 34.0, 27.2, 27.1, 17.2; HRMS (ESI) calcd forC18H22O4 [M+H]+ 303.1596, found 303.1598.
化合物25的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (s, 1H), 5.93 (s, 1H), 5.61 (s, 1H), 5.43(s, 1H), 5.20 (s, 1H), 4.80 (s, 1H), 4.52 (t, J = 4.2 Hz, 1H), 3.03 (dt, J =11.9, 6.1 Hz, 1H), 2.23 (d, J = 15.3 Hz, 2H), 1.97 – 1.82 (m, 2H), 1.74 (ddd,J = 13.9, 7.0, 2.3 Hz, 1H), 1.64 – 1.52 (m, 2H), 1.49 – 1.41 (m, 1H), 1.35(q, J = 12.6 Hz, 1H), 0.85 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 163.4,144.1, 141.9, 120.7, 114.3, 79.3, 76.6, 64.8, 41.5, 41.0, 40.4, 36.3, 33.9,27.0, 26.8, 17.1; HRMS (ESI) calcd for C17H20Cl2O4 [M+H]+ 359.0817, found359.0808.
化合物26的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (s, 1H), 5.59 (s, 1H), 5.36 (s, 1H), 5.13(s, 1H), 4.70 (s, 1H), 4.52 (t, J = 4.4 Hz, 1H), 3.02 (dt, J = 11.8, 6.0 Hz,1H), 2.32 (q, J = 7.5 Hz, 2H), 2.22 (d, J = 14.8 Hz, 2H), 1.79 (m, 2H), 1.72(dd, J = 12.9, 6.0 Hz, 1H), 1.56 (m, 2H), 1.38 (m, 2H), 1.13 (t, J = 7.6 Hz,3H), 0.83 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 173.6, 170.6, 145.7, 142.1,120.5, 112.6, 76.7, 75.2, 41.6, 41.1, 40.5, 36.5, 34.0, 28.1, 27.2, 27.1,17.2, 9.3; HRMS (ESI) calcd for C18H24O4 [M+H]+ 305.1753, found 305.1755.
化合物27的合成
1H NMR (400 MHz, CDCl3) δ 6.15 (d, J = 0.8 Hz, 1H), 5.60 (s, 1H), 5.32(t, J = 2.7 Hz, 1H), 5.13 (s, 1H), 4.70 (s, 1H), 4.52 (dd, J = 4.8, 3.5 Hz,1H), 3.08 – 2.95 (m, 1H), 2.23 (m, 2H), 1.83 – 1.78 (m, 2H), 1.74 (ddd, J =13.9, 7.0, 2.6 Hz, 1H), 1.61 – 1.56 (m, 1H), 1.53 (m, 1H), 1.45 – 1.31 (m,2H), 1.20 (s, 9H), 0.85 (s, 3H) .13C NMR (101 MHz, CDCl3) δ 177.5, 170.6,145.7, 142.1, 120.5, 112.5, 76.7, 75.1, 41.8, 41.3, 40.6, 39.1, 36.8, 34.0,27.3, 27.2, 27.1, 17.1.
化合物28的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (d, J = 0.8 Hz, 1H), 5.59 (s, 1H), 5.35(t, J = 2.7 Hz, 1H), 5.13 (s, 1H), 4.70 (s, 1H), 4.52 (td, J = 4.8, 1.4 Hz,1H), 3.08 – 2.97 (m, 1H), 2.26 (d, J = 7.7, 1H), 2.23 (d, J = 10.8, 1H), 1.87– 1.70 (m, 3H), 1.64 – 1.56 (m, 3H), 1.44 – 1.30 (m, 2H), 0.98 (m, 2H), 0.86(m, 1H), 0.84 (s, 3H), 0.84 – 0.81 (m, 1H) ;13C NMR (101 MHz, CDCl3) δ 174.0,170.6, 145.7, 142.1, 120.5, 112.6, 76.8, 75.4, 41.7, 41.2, 40.6, 36.6, 34.0,27.2, 27.1, 17.2, 13.4, 8.7, 8.6.
化合物29的合成
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.6 Hz, 5H), 6.13 (s, 1H), 5.59(s, 1H), 5.33 (s, 1H), 5.11 (s, 1H), 4.67 (s, 1H), 4.47 (s, 1H), 3.61 (s,2H), 2.90 (s, 1H), 2.16 (d, J = 15.1 Hz, 1H), 1.96 (d, J = 11.7 Hz, 1H), 1.69(d, J = 64.9 Hz, 4H), 1.49 – 1.14 (m, 6H), 0.79 (s, 3H) ；13C NMR (101 MHz,CDCl3) δ 170.5, 170.4, 145.4, 142.0, 134.6, 129.4, 128.6, 127.0, 120.4,112.6, 76.6, 75.8, 42.0, 41.2, 41.0, 40.4, 36.3, 33.8, 27.0, 26.9, 17.1.
化合物30的合成
1H NMR (400 MHz, CDCl3) δ 6.13 (s, 1H), 5.59 (s, 1H), 5.33 (s, 1H), 5.12(s, 1H), 4.69 (s, 1H), 4.52 (t, J = 4.2 Hz, 1H), 3.08 – 2.96 (m, 1H), 2.28(m, 1H), 2.22 (d, J = 14.2 Hz, 2H), 1.88 (m, 2H), 1.83 – 1.67 (m, 5H), 1.67 –1.53 (m, 3H), 1.48 – 1.32 (m, 4H), 1.30 – 1.21 (m, 3H), 0.83 (s, 3H) ;13C NMR(101 MHz, CDCl3) δ 174.9, 170.4, 145.7, 142.0, 120.3, 112.4, 76.6, 74.8,43.4, 41.6, 41.1, 40.4, 36.5, 33.9, 29.2, 28.9, 27.1, 27.0, 25.8, 25.5, 25.4,17.0.
化合物31的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (s, 1H), 5.60 (s, 1H), 5.34 (s, 1H), 5.13(s, 1H), 4.70 (s, 1H), 4.52 (t, J = 4.6 Hz, 1H), 3.02 (dt, J = 11.9, 6.2 Hz,1H), 2.81 – 2.66 (m, 1H), 2.23 (d, J = 15.0 Hz, 2H), 1.97 – 1.64 (m, 9H),1.57 (m, 4H), 1.43 – 1.30 (m, 2H), 0.84 (s, 3H) ；13C NMR (101 MHz, CDCl3) δ175.8, 170.6, 145.8, 142.1, 120.5, 112.5, 76.7, 75.0, 44.3, 41.7, 41.2, 40.5,36.6, 34.0, 30.2, 29.9, 27.2, 27.1, 25.9, 25.9, 17.1.
化合物32的合成
1H NMR (400 MHz, CDCl3) δ 8.06 – 7.87 (m, 2H), 7.41 (d, J = 7.5 Hz, 2H),6.13 (s, 1H), 5.58 (s, 2H), 5.24 (s, 1H), 4.77 (s, 1H), 4.53 (s, 1H), 3.03(dt, J = 11.6, 5.9 Hz, 1H), 2.28 (t, J = 13.1 Hz, 2H), 1.92 (d, J = 14.9 Hz,2H), 1.73 (dd, J = 21.9, 7.7 Hz, 2H), 1.61 (dd, J = 15.8, 4.4 Hz, 1H), 1.49 –1.40 (m, 1H), 1.38 – 1.29 (m, 1H), 0.88 (s, 3H)；13C NMR (100 MHz, CDCl3) δ170.5, 164.7, 145.3, 142.0, 139.4, 131.0, 129.3, 128.8, 120.6, 113.3, 76.6,76.3, 41.9, 41.2, 40.4, 36.8, 34.1, 27.3, 27.0, 17.2.
化合物33的合成
1H NMR (400 MHz, CDCl3)δ 6.11 (s, 1H), 5.58 (s, 1H), 5.30 (s, 1H), 5.09(s, 1H), 4.67 (s, 1H), 4.50 (t, J = 4.0 Hz, 1H), 3.01 (dt, J = 11.8, 6.2 Hz,1H), 2.43 – 2.30 (m, J = 8.9, 4.3 Hz, 1H), 2.20 (d, J = 14.4 Hz, 2H), 1.95 –1.83 (m, 2H), 1.76 (dt, J = 7.1, 3.8 Hz, 2H), 1.69 (d, J = 11.6, 4.7, 3.5 Hz,3H), 1.64 (s, 1H), 1.62 (d, J = 4.3 Hz, 1H), 1.58 – 1.45 (m, 8H), 1.41 – 1.27(m, 2H), 0.81 (s, 3H)；13C NMR (100 MHz, CDCl3) δ 176.0, 170.5, 145.7, 142.0,120.4, 112.4, 76.7, 74.8, 45.3, 41.6, 41.1, 40.4, 36.5, 33.9, 31.0, 30.7,28.4, 28.3, 27.1, 27.0, 26.4, 26.3, 17.1.
化合物34的合成
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.20 (m, 3H), 6.14 (s,1H), 5.60 (s, 1H), 5.35 (s, 1H), 5.12 (s, 1H), 4.68 (s, 1H), 4.50 (t, J = 4.2Hz, 1H), 2.97 (m, 3H), 2.65 (t, J = 7.7 Hz, 2H), 2.18 (d, J = 15.5 Hz, 1H),2.08 (d, J = 12.5 Hz, 1H), 1.76 (m, 2H), 1.71 – 1.61 (m, 1H), 1.47 (m, 2H),1.38 – 1.24 (m, 2H), 0.81 (s, 3H) ；13C NMR (101 MHz, CDCl3) δ 171.9, 170.5,145.5, 142.0, 140.5, 128.5, 128.3, 126.3, 120.4, 112.6, 76.6, 75.4, 41.4,40.9, 40.4, 36.3, 36.1, 33.8, 31.0, 27.0, 26.9, 17.1.
化合物35的合成
1H NMR (400 MHz, CDCl3) δ 8.43 (s, 2H), 8.06 (s, 1H), 6.14 (s, 1H), 5.66(s, 1H), 5.59 (s, 1H), 5.29 (s, 1H), 4.84 (s, 1H), 4.55 (d, J = 4.5 Hz, 1H),3.06 (dt, J = 11.4, 5.9 Hz, 1H), 2.27 (m, 2H), 2.06 – 1.90 (m, 2H), 1.77 (dd,J = 13.6, 6.9 Hz, 1H), 1.66 (m, 2H), 1.53 (d, J = 13.4 Hz, 1H), 1.42 – 1.34(m, 1H), 0.90 (s, 3H) ；13C NMR (101 MHz, CDCl3) δ 170.5, 163.1, 144.7, 141.9,133.1, 132.3 (q, J = 34.0 Hz), 129.7, 126.4 (m), δ 123.0 (q, J = 273.0 Hz),120.7, 114.2, 77.6, 76.6, 42.0, 41.1, 40.4, 36.8, 34.0, 27.1, 27.0, 17.1.
化合物36的合成
1H NMR (400 MHz, CDCl3) δ 6.14 (s, 1H), 5.59 (s, 1H), 5.36 (t, J = 2.6Hz, 1H), 5.13 (s, 1H), 4.69 (s, 1H), 4.52 (dd, J = 4.7, 3.6 Hz, 1H), 3.10 –2.95 (m, 1H), 2.27 (t, J = 7.4 Hz, 2H), 2.22 (d, J = 15.2 Hz, 2H), 1.84 –1.51 (m, 8H), 1.37 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H), 0.83 (s, 3H) ；13C NMR(100 MHz, CDCl3) δ 172.8, 170.6, 145.7, 142.1, 120.5, 112.6, 76.7, 75.1,41.6, 41.1, 40.5, 36.8, 36.5, 34.0, 27.2, 27.1, 18.7, 17.2, 13.8.
化合物37-42的合成路线：
将烘干的10 mL圆底烧瓶中加入酸（Ⅲ），加入溶剂二氯甲烷，开始搅拌，然后加入1.1eq的草酰氯加入0.1 eq的N,N–二甲基甲酰胺，2 h后将反应处理，真空浓缩即得化合物酰氯（Ⅳ）。将化合物2溶于DCM中，加入1.5 eq的三乙胺（TEA），搅拌1–2 min后加入1.2 eq的酰氯，室温下搅拌1 h，用TLC检测反应完全，用蒸馏水淬灭反应，用DCM萃取三次，合并有机相，用无水Na2SO4干燥，过滤，滤液减压浓缩，过硅胶色谱柱（石油醚/乙酸乙酯）得目标化合物37-42（白色无定型固体）。
化合物37的合成
1H NMR (400 MHz, CDCl3) δ 8.77 (s, 1H), 8.62 (s, 1H), 7.85 (d, J = 7.6Hz, 1H), 7.66 (d, J = 16.1 Hz, 1H), 7.35 (s, 1H), 6.53 (d, J = 18.1 Hz, 1H),6.15 (s, 1H), 5.60 (s, 1H), 5.52 (s, 1H), 5.22 (s, 1H), 4.77 (s, 1H), 4.55(s, 1H), 3.14 – 2.98 (m, 1H), 2.35 – 2.23 (m, 2H), 1.90 (d, J = 15.4 Hz, 2H),1.63 (d, J = 13.6 Hz, 2H), 1.46 (d, J = 17.8 Hz, 2H), 1.29 (s, 1H), 0.88 (s,3H)；13C NMR (100 MHz, CDCl3) δ 170.5, 165.4, 151.0, 149.6, 145.4, 142.0,141.0, 134.5, 130.4, 123.9, 120.9, 120.5, 113.1, 76.7, 75.9, 41.7, 41.1,40.5, 36.6, 34.0, 29.8, 27.2, 17.7. HRMS (ESI) calcd for C23H25NO4 [M+H]+380.1856, found 380.1863.
化合物38的合成
1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 7.78 – 7.62 (m, 2H), 7.44 (d, J =8.1 Hz, 1H), 7.30 (s, 1H), 6.94 (d, J = 15.7 Hz, 1H), 6.15 (s, 1H), 5.60 (s,1H), 5.50 (s, 1H), 5.20 (s, 1H), 4.74 (s, 1H), 4.54 (s, 1H), 3.07 – 2.97 (m,1H), 2.28 (dd, J = 28.7, 13.5 Hz, 2H), 1.87 (d, J = 12.0, 10.7 Hz, 2H), 1.62(d, J = 20.0 Hz, 3H), 1.43 (d, J = 10.7 Hz, 2H), 0.86 (s, 3H); 13C NMR (100MHz, CDCl3) δ 170.5, 165.8, 153.0, 150.3, 143.3, 142.1, 137.1, 124.5, 124.4,123.0, 120.6, 112.8, 76.8, 75.7, 41.6, 41.1, 40.5, 36.5, 34.1, 27.3, 27.1,17.2. HRMS (ESI) calcd for C23H25NO4 [M+H]+ 380.1856, found 380.1858.
化合物39的合成
1H NMR (400 MHz, CDCl3) δ 8.65 (d, J = 6.0 Hz, 2H), 7.58 (d, J = 16.0 Hz,1H), 7.37 (d, J = 6.0 Hz, 2H), 6.60 (d, J = 16.0 Hz, 1H), 6.15 (s, 1H), 5.59(s, 1H), 5.50 (s, 1H), 5.21 (s, 1H), 4.76 (s, 1H), 4.53 (t, J = 4.2 Hz, 1H),3.03 (dt, J = 11.9, 6.3 Hz, 1H), 2.32 – 2.21 (m, 2H), 1.89 (dt, J = 14.3, 3.3Hz, 2H), 1.75 (dd, J = 14.0, 7.0 Hz, 1H), 1.69 – 1.56 (m, 2H), 1.45 (d, J =18.3 Hz, 1H), 1.41 – 1.31 (m, 1H), 0.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ170.5, 165.2, 150.7, 145.3, 142.0, 141.9, 141.7, 123.3, 121.9, 120.6, 113.3,76.7, 76.1, 41.7, 41.1, 40.5, 36.6, 34.1, 27.2, 27.1, 17.2. HRMS (ESI) calcdfor C23H25NO4 [M+H]+ 380.1856, found 380.1848.
化合物40的合成
1H NMR (400 MHz,CDCl3) δ 9.21 (s, 1H), 8.77 (d, J = 4.1 Hz, 1H), 8.28 (d,J = 7.9 Hz, 1H), 7.46 – 7.37 (m, 1H), 6.13 (s, 1H), 5.63 (s, 1H), 5.58 (s,1H), 5.25 (s, 1H), 4.78 (s, 1H), 4.53 (t, J = 4.2 Hz, 1H), 3.02 (dt, J =11.8, 6.1 Hz, 1H), 2.35 – 2.22 (m, 2H), 1.94 (d, J = 14.9, 13.6 Hz, 3H), 1.73(s, 2H), 1.61 (d, J = 15.6 Hz, 1H), 1.50 (d, J = 13.3 Hz, 1H), 1.38 (d, J =12.7 Hz, 1H), 0.88 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 164.2, 153.5,150.9, 145.1, 142.0, 137.3, 126.8, 123.5, 120.6, 113.5, 76.6, 76.6, 41.9,41.2, 40.5, 36.8, 34.1, 27.3, 27.1, 17.2. HRMS (ESI) calcd for C21H23NO4 [M+H]+354.1694, found 354.1706.
化合物41的合成
1H NMR (400 MHz, CDCl3) δ 8.89–8.67 (m, 1H), 8.07 (d, J = 7.8 Hz, 1H),7.83 (t, J = 7.5 Hz, 1H), 7.47 (s, 1H), 6.13 (s, 1H), 5.66 (s, 1H), 5.57 (s,1H), 5.26 (s, 1H), 4.78 (s, 1H), 4.52 (s, 1H), 3.03 (dt, J = 10.8, 5.8 Hz,1H), 2.37 (d, J = 12.5 Hz, 1H), 2.24 (d, J = 15.5 Hz, 1H), 1.92 (t, J = 14.6Hz, 1H), 1.80 – 1.69 (m, 2H), 1.68 – 1.59 (m, 1H), 1.51–1.35 (m, 2H), 0.88(s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.6, 164.3, 150.1, 148.7, 145.2, 142.1,137.0, 126.8, 125.1, 120.5, 113.6, 77.0, 76.8, 41.8, 41.1, 40.5, 36.7, 34.0,27.2, 27.1, 17.2. HRMS (ESI) calcd for C21H23NO4 [M+H]+ 354.1700, found354.1707.
化合物42的合成
1H NMR (400 MHz, CDCl3) δ 8.79 (s, 2H), 7.84 (s, 2H), 6.15 (s, 1H), 5.61(d, J = 13.0 Hz, 2H), 5.27 (s, 1H), 4.81 (s, 1H), 4.55 (s, 1H), 3.05 (s, 1H),2.29 (d, J = 14.3 Hz, 2H), 1.95 (d, J = 13.5 Hz, 2H), 1.80 – 1.58 (m, 4H),1.52 (d, J = 13.4 Hz, 1H), 1.39 (d, J = 13.7 Hz, 1H), 0.89 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 170.6, 164.1, 150.7, 144.9, 141.9, 138.1, 123.0, 120.7,113.9, 77.1, 76.6, 42.0, 41.1, 40.5, 36.8, 34.1, 27.2, 27.0, 17.2. HRMS (ESI)calcd for C21H23NO4 [M+H]+ 354.1700, found 354.1703.
实施例18：异土木香内酯及其衍生物的药理作用
将各种癌细胞配成2×105/mL细胞悬液，加入24孔板圆底细胞培养板内，分别加入待测化合物，每一测试浓度5孔，置37 ℃、5%CO2饱和湿度条件下培养72小时，用MTT法在酶联检测仪570 nm波长测得吸光度（A）值，计算出本发明化合物对测试癌细胞的抑制作用。
表1 异土木香内酯及其衍生物对各种癌细胞的抑制活性（IC50，μM）
其中HL-60、HL-60/A、KG1a分别表示急性白血病细胞株、耐阿霉素急性白血病细胞株、人白血病细胞株。
活性测试结果表明，筛选的化合物对受试细胞显示出抑制活性。因此测试化合物具有用于治疗癌症的用途。
本发明的化合物、用途和方法已经通过具体的实施例进行了描述。本领域技术人员可以借鉴本发明的内容适当改变原料、工艺条件等环节来实现相应的其它目的，其相关改变都没有脱离本发明的内容，所有类似的替换和改动对于本领域技术人员来说是显而易见的，都被视为包括在本发明的范围之内。

Claims (8)

1.一种如下式（I）的化合物，
（I）
其中，R为烷基、环烷基、烯基、芳基、烷基芳基、芳基烷基、芳基烯基、杂环基、吡啶环基、芳氧烷基。
2.根据权利要求1所述的化合物，化合物为3–42，
。
3.本发明还提供了一种式（I）的异土木香内酯衍生物或其盐在制备治疗癌症的药物中的用途，其中癌症为白血病。
4.本发明还提供了一种式（I）的异土木香内酯衍生物或其盐在制备治疗癌症的辅助药物中的用途，其中癌症为白血病。
5.本发明还提供了一种用于治疗癌症的药物组合物，其中含有有效量的式（I）的异土木香内酯衍生物和药学上可接受的载体或与其他抗癌药物的组合物。
6.本发明还提供了式3–42化合物在制备治疗癌症的药物中的用途，其中癌症为白血病。
7.本发明还提供了式3–42化合物在制备治疗癌症的辅助药物中的用途，其中癌症为白血病。
8.本发明还提供了一种用于治疗癌症的药物组合物，其中含有有效量的式3–42化合物和药学上可接受的载体或与其他抗癌药物的组合物。
CN201710528898.3A 2017-07-01 2017-07-01 异土木香内酯衍生物，其药物组合物及其用途 Active CN109206389B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710528898.3A CN109206389B (zh) 2017-07-01 2017-07-01 异土木香内酯衍生物，其药物组合物及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710528898.3A CN109206389B (zh) 2017-07-01 2017-07-01 异土木香内酯衍生物，其药物组合物及其用途

Publications (2)

Publication Number Publication Date
CN109206389A true CN109206389A (zh) 2019-01-15
CN109206389B CN109206389B (zh) 2022-07-26

Family

ID=64993095

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710528898.3A Active CN109206389B (zh) 2017-07-01 2017-07-01 异土木香内酯衍生物，其药物组合物及其用途

Country Status (1)

Country Link
CN (1) CN109206389B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111892563A (zh) * 2020-08-26 2020-11-06 河南中医药大学 化合物3β-acetoxyl-atractylenolide I、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104739825A (zh) * 2015-02-25 2015-07-01 上海交通大学医学院附属第三人民医院 异土木香内酯在制备抗慢性粒细胞性白血病药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104739825A (zh) * 2015-02-25 2015-07-01 上海交通大学医学院附属第三人民医院 异土木香内酯在制备抗慢性粒细胞性白血病药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. YOSHIOKA，ET AL.: "Structure and Stereochemistry of Pulchellin B, C, E, and F", 《THE JOURNAL OF ORGANIC CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111892563A (zh) * 2020-08-26 2020-11-06 河南中医药大学 化合物3β-acetoxyl-atractylenolide I、制备方法和用途
CN111892563B (zh) * 2020-08-26 2022-12-09 河南中医药大学 化合物3β-acetoxyl-atractylenolide I、制备方法和用途

Also Published As

Publication number Publication date
CN109206389B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
CN108299458B (zh) 冬凌草甲素衍生物及其制备方法和应用
CN113336705B (zh) 一种大麻二酚-2-咪唑-1-甲酸酯及其应用
CN103044395B (zh) 含有地氯雷他定结构的氨基酸类衍生物、其制备方法和用途
US8796279B2 (en) 4′-demethylepipodophyllotoxin derivative, preparation method and use thereof
CN106243182B (zh) 甘草次酸-硫化氢供体试剂衍生物及其合成方法和应用
CN106243183B (zh) 熊果酸-硫化氢供体试剂衍生物及其合成方法
CN108484632B (zh) 青蒿素-苯胺基喹唑啉类衍生物及其制备方法和应用
CN111072682A (zh) 白屈菜碱呋咱类一氧化氮供体衍生物及其制备方法和用途
CN110642740B (zh) 异斯特维醇酰胺衍生物及其制备方法
CN107286220B (zh) 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用
CN103193754A (zh) 7-酰基-15-氧代绣线菊内酯衍生物及其制备方法和用途
CN110981882B (zh) 一类白屈菜碱一氧化氮供体衍生物及其制备方法和用途
CN110981881B (zh) 白屈菜碱一氧化氮供体衍生物及其制备方法和用途
CN109206389A (zh) 异土木香内酯衍生物，其药物组合物及其用途
CN104771392B (zh) 一类组蛋白去乙酰化酶抑制剂及应用
CN108456239A (zh) 具有抗肿瘤作用的化合物ba-x及其制备方法和应用
CN110028477B (zh) 一类布雷菲德菌素a的4-位拼合氮芥衍生物的制备方法和用途
CN107365265B (zh) 夹竹桃麻素水溶性前药、其制备方法、药物组合物及用途
JPH01249777A (ja) 新規なカンプトテシン誘導体及びその製造法
RU2686675C1 (ru) Таксановые соединения, а также способ их получения и их применения
CN102485735B (zh) 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
CN102786458B (zh) 吡咯甲酰胺衍生物、其制备方法和用途
CN106565657A (zh) 一种具抗肿瘤活性的橙皮素肉桂酸酯类化合物及其合成方法
CN109867708B (zh) 具有抗肿瘤作用的甘草次酸系列衍生物(tnga-x)的制备方法和应用
CN109867709B (zh) 具有抗肿瘤作用的甘草次酸系列衍生物(toga-x)的制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant